3/5/2014

Advanced Accelerator Applications' gallium-68 DOTATATE, a radiopharmaceutical used in PET/CT imaging of gastro-entero-pancreatic neuroendocrine tumors, has been granted orphan drug status by the FDA and the European Medicines Agency. Preliminary data suggest the agent will improve cancer diagnosis while reducing radiation exposure.

Full Story:
News-Medical.Net

Related Summaries